Estimates Revisions Outlook Therapeutics, Inc.
Stocks
OTLK
US69012T3059
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
00:00:00 19/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.7000 USD | +4.14% |
|
-39.13% | -55.70% |
| 08-17 | EyePoint's drug for age-related eye disease fails late-stage trial, shares tank | RE |
| 08-17 | Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- OTLK Stock
- Consensus Outlook Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
